NeuBase Therapeutics, Inc.
NBSEDelisted May 16, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001173281
NeuBase Therapeutics, Inc. was delisted on May 16, 2024; its insiders filed their last Form 4 on Sep 18, 2023; 18 institutions reported holding it in 13F filings for Q1 2024, worth $177.1K in total; Greenlight Capital was the only superinvestor holding it.
Q3 2023 vs. Q2 2023
How the institutions holding NeuBase Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 26 | 20 | −6 |
| Shares | 578.9K | 347.0K | −231.9K (−40.1%) |
| Value | $1.08M | $301.2K | −$780.7K (−72.2%) |
New holders (1)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 12,354 | $10.7K | 0.00% |
Sold out (7)
Institutions that held NeuBase Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Armistice Capital, LLC | 166,174 | $310.7K |
| Decheng Capital Management III (Cayman), LLC | 50,000 | $92.5K |
| Renaissance Technologies LLC | 12,601 | $24.0K |
| CM Management, LLC | 6,000 | $11.0K |
| JPMorgan Chase & Co | 539 | $997 |
| IFP Advisors, Inc | 105 | $469 |
| UBS Group AG | 68 | $127 |